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Abstract
Summary Based on this double-blind, placebo-controlled
study, ibandronate has no beneficial effect on clinical and
radiological outcome in patients with spontaneous
osteonecrosis of the knee over and above anti-inflammatory
medication.
Introduction Observational studies suggest beneficial effects
of bisphosphonates in spontaneous osteonecrosis (ON) of the
knee. We investigated whether ibandronate would improve
clinical and radiological outcome in newly diagnosed ON.
Methods In this randomized, double-blind, placebo-
controlled trial, 30 patients (mean age, 57.3±10.7 years) with
ON of the knee were assigned to receive either ibandronate
(cumulative dose, 13.5 mg) or placebo intravenously (divided
into five doses 12 weeks). All subjects received additional
treatment with oral diclofenac (70 mg) and supplementation
with calcium carbonate (500mg) and vitamin D (400 IU) to be
taken daily for 12weeks. Patients were followed for 48weeks.
The primary outcome was the change in pain score after
12 weeks. Secondary endpoints included changes in pain
score, mobility, and radiological outcome (MRI) after
48 weeks.
Results At baseline, both treatment groups (IBN, n =14; pla-
cebo, n =16) were comparable in relation to pain score and
radiological grading (bone marrow edema, ON). After
12 weeks, mean pain score was reduced in both ibandronate-
(mean change, −2.98; 95 % CI, −4.34 to −1.62) and placebo-
(−3.59; 95 % CI, −5.07 to −2.12) treated subjects (between-
group comparison adjusted for age, sex, and osteonecrosis
type, p =ns). Except for significant decrease in bone resorp-
tion marker (CTX) in ibandronate-treated subjects (p <0.01),
adjusted mean changes in all functional and radiological out-
come measures were comparable between treatment groups
after 24 and 48 weeks.
Conclusions In patients with spontaneous osteonecrosis of
the knee, bisphosphonate treatment (i.e., IV ibandronate) has
no beneficial effect over and above anti-inflammatory
medication.
Keywords Bisphosphonate . Bonemarrow edema .
Ibandronate . Osteonecrosis
Introduction
Osteonecrosis (ON) of the knee occurs as a localized inflam-
matory disease which may progress to subchondral bone
collapse and disabling osteoarthritis. Based on its pathophys-
iological mechanism, ON is generally classified in three
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distinct entities: spontaneous ON of the knee, postarthroscopic
ON, and secondary ON in relation to systemic disease (e.g.,
corticosteroid use, alcoholism, myeloproliferative disorders)
[1–4]. Spontaneous ON of the knee (SONK, Morbus
Ahlbäck) is characterized by a sudden onset of knee pain,
affects predominantly women over 55 years, and mostly in-
volves the medial femoral condylar epiphysis [5, 6]. Specific
risk factors for ON are absent in this type of condition;
however, vascular insufficiency with compromised micro-
circulation leading to infarction of bone and minor unrec-
ognized traumatic insults producing microfractures in the
subchondral bone have been discussed [7]. Most reports on
postarthroscopic ON occur at the medial femoral condyle
[8]. Its etiology is thought to be related to occult damage to
the cartilage and meniscus during arthroscopy; however,
prearthroscopic meniscal tears or subchondral fracture with
altered biomechanics may predispose to tissue injury after
arthroscopy [7].
Although early stage spontaneous ON of the knee may
respond favorably to nonsurgical management, progressive
disease has poor prognosis requiring osteotomy or
arthroplasty [5]. Bisphosphonates inhibit bone resorption
and are widely used in metabolic bone diseases character-
ized by increased osteoclastic activity (i.e., osteoporosis
and Paget’s disease of bone). The rationale for the use of
bisphosphonates in the treatment of early, precollapse stage
ON is based on the assumption that the structural bone
failure is the result of resorption of necrotic bone during
revascularization before new bone has been formed. It can
be hypothesized that if accelerated bone resorption could be
reduced during the revascularization process until sufficient
new bone has been formed, it would appear that structural
failure could be avoided. In animal studies, it has been
shown that bisphosphonates prevent resorption of necrotic
bone during revascularization and ischemic necrosis with
preservation of the histologic and macroscopic bone archi-
tecture [9–11]. In humans, bisphosphonate treatment has
been used in bone marrow edema [12] or avascular necrosis
of the femoral head [13–16]. Specifically, favorable results
of alendronate and pamidronate treatment, particularly in
diminishing pain, improving mobility, and lowering the
incidence of articular collapse in avascular necrosis of the
hip, have been reported [17].
Studies investigating the effect of bisphosphonates in pa-
tients with spontaneous or postarthroscopic ON of the knee
are limited. Nevertheless, a case report [18] and three obser-
vational studies [19–21] suggest a beneficial effect of various
bisphosphonate regimens on clinical and radiological out-
come. All studies, however, are limited by small sample size,
short duration, and/or uncontrolled study design.
Based on this apparent beneficial effect of bisphosphonates
in the treatment of osteonecrosis of the knee, we aimed to
investigate the efficacy of ibandronate on clinical (pain score
andmobility) and radiological (MRI) outcome in patients with
newly diagnosed spontaneous or postarthroscopic ON of the
femoral condyles using a randomized, double-blind, placebo-
controlled study design.
Materials and methods
Study design and participants
This study was a 1-year randomized, double-blind, placebo-
controlled trial of ibandronate in patients with newly diag-
nosed spontaneous or postarthroscopic osteonecrosis of the
knee. Participants were randomized to receive 13.5 mg
ibandronate (Bonviva IV; Roche Pharma AG, Switzerland)
or placebo intravenously divided in four injections within
2 weeks (once 1.5 mg then 3 mg per injection) and followed
by a fifth injection after 3 months (3 mg). In addition, all
patients received daily calcium (500 mg) and vitamin D
(400 IU) throughout the study and diclofenac (50 mg/day)
for the first 3 months. Weight-bearing was not restricted.
Patients, investigator staff, persons performing the assess-
ment, and data analysts remained blinded from the time of
randomization until database lock.
All participants provided written informed consent
before any study procedures were performed. The study
was conducted in accordance with the principles of
GCP and was approved by the local Ethics Committee
for Human Studies. The study was registered at
ClinicalTrials.gov (NCT00532220).
All study participants were recruited and followed at one
single outpatient clinic. Eligible patients were women and
men, aged between 20 and 75 years, in satisfactory general
health and with newly diagnosed osteonecrosis in the medial
or lateral femoral condyles. Osteonecrosis and/or bone mar-
row edema were confirmed by magnetic resonance imaging
(MRI) scan. Exclusion criteria included the inability to pro-
vide informed consent, presence of renal insufficiency (calcu-
lated creatinine clearance <50 ml/min), or hypocalcemia (S-
calcium <2.0 mmol/l) prior treatment with bisphosphonates or
calcitonin (2 years before study entry), premenopausal women
without adequate contraception, and hypersensitivity to
bisphosphonates. Furthermore, patients were excluded when
reporting conditions that might preclude the participant from
adhering to the protocol or completing the trial per protocol.
We enrolled participants between December 2007 and June
2010.
Study procedures
After a 4-week run-in phase (screening procedures), eligible
participants provided written informed consent were random-
ized to receive ibandronate or placebo and were followed for
360 Osteoporos Int (2014) 25:359–366
48 weeks. At baseline information on demographics, health
history and medication use was obtained. Clinical evaluations
[including visual analogue pain scale (VAS), Western Ontario
and McMaster Universities physical function and stiffness
score (WOMAC), and International Knee Documentation
Committee subjective knee form (IKDC) questionnaires] were
performed at baseline and at weeks 2, 4, 12, 24, and 48.
Morning blood samples were drawn after an overnight fast
including routine chemistry and biochemical markers of bone
turnover [alkaline phosphatase (ALP), N-terminal propeptide
of type I procollagen (PINP), and C-terminal type I collagen
telopeptide (CTX)] at baseline and at weeks 4, 12, 24, and 48.
MRI scans were performed at baseline and after 12 and
48 weeks. Clinical and functional outcome was assessed by
VAS, WOMAC, and IKDC [22–27].
Calcium, creatinine, and total alkaline phosphatase were
analyzed by standard method on an autoanalyzer (Hitachi
System 704 analyzer; Roche Diagnostics, Switzerland). β-
CrossLaps (CTX) and PINP were measured in serum with
an electrochemiluminescence immunoassay on the automated
analyzer Elecsys 2010 (Roche Diagnostics, Switzerland) [28].
The intra- and interassay variations were 2.4 and 7.2 % for
CTX and 1.7 and 4.0 % for PINP.
All magnetic resonance images were interpreted by one
single MSK trained radiologist blinded to clinical data (TW).
MR imaging of the knee was performed on a 3 Tesla MRI
System (Verio, Siemens Medical Systems, Germany) using a
standard knee protocol with a dedicated 15 channel knee coil.
Sagittal and coronal proton density (PD) sequences, coronal
T2-weighted images with fat saturation (FS), and sagittal PD
FS images were obtained. For each patient and visit, the
following parameters were visually assessed and graded
accordingly:
Bone marrow edema Bone marrow edema (BME) was de-
fined by areas of decreased signal intensity of subchondral
bone on PD-weighted MRI and increased signal intensity on
T2-weighted images. BME was graded using the Whole Or-
gan Magnetic Resonance Imaging Score (WORMS) method
[29]. WORMS is a validated research tool for semiquantita-
tive assessment of knee OA. In WORMS, subchondral BME
is scored from 0 to 3 based on the extent of subregional
involvement (0, none; 1, <25 % of the subregion; 2, 25–
50 %; 3, >50 %).
ON ON was graded according to the Ficat Classification
adapted to MRI (stage 0: normal, stage I: edema and mild
cortical irregularity, stage II: geographic defect of cortical bone,
stage III: crescent sign and cortical collapse, stage IV: evidence
of secondary degenerative change such as subchondral cyst
formation) [30]. All areas of ON were localized using a com-
partmental approach (medial vs. lateral femoral condyle, central
location vs. anterior vs. posterior location).
Objective and endpoints
The primary objective of the study was to evaluate the change
in pain score (VAS) after 12 weeks treatment with ibandronate
or placebo. Secondary objectives included evaluation of the
changes in mobility (WOMAC and IKDC questionnaires) and
biochemical markers of bone turnover after 12 weeks, radio-
logical outcome (MRI) after 24 and 48 weeks, and dropout
rate after 12 weeks. A decrease in VAS score by 50 %, a
decrease in WOMAC questionnaire by 26 % [31], and a gain
in IKDC score by more than 24 points [32] would be consid-
ered clinically significant. At enrollment, patients were in-
formed that in case of dropout after 12 weeks due to persistent
pain, salvage therapy (ibandronate as per protocol) will be
offered to patients experiencing persistent disease randomized
to the placebo group. In case of dropout, study protocol
allowed to unblind individual randomization codes while
ascertaining strict blinding of randomization to all other par-
ticipants continuing the study.
We hypothesized that there was a significant difference
between the two treatment groups; hence, ibandronate was
assumed to be superior in reducing pain, improving functional
mobility, and improving radiological changes.
Statistical analysis
The sample size calculation considered the primary objective
of the study to show superiority of ibandronate relative to
placebo for the beneficial effect on knee pain (VAS score).
The choice of the sample size was based on the conservative
assumption that ibandronate will produce a 50 % reduction in
average pain score from VAS 8.2 to 4.1 (based on data from
our previously published observational study) [19] whereas
the corresponding reduction under placebo was 30 % (i.e.,
VAS from 8.2 to 5.7). We further assumed that the standard
deviation of individual pain scores after treatment equals 1
unit. Under these assumptions, it was followed that 10 patients
per group would guarantee a 90% probability of observing an
effect difference that is statistically significant at the 5 % level.
Based on this sample size calculation and adjusting for a
dropout rate of approximately 30 % in each treatment group,
the required total sample size of 30 was assumed to evaluate
the primary efficacy objective.
Continuous variables were summarized as mean ± SD and
as median and interquartile ranges, respectively. Categorical
variables were summarized as counts and proportions. Base-
line characteristics of patients in the treatment and placebo
groups were compared using the Fisher’s exact test or the
Mann Whitney U test. For intention-to-treat analyses, gener-
alized linear model regressions were performed to calculate
the outcome difference between the two groups adjusted by
age, sex, and osteonecrosis type. The Dunnet-Hsu adjustment
for multiple comparisons was applied. p <0.05 was
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considered statistically significant. Analyses were done using
SAS software version 9.2 (SAS Institute Inc., USA).
Results
From December 2007 to June 2010, 30 consecutive patients
were enrolled in this study and randomized to ibandronate
(n =14) or placebo (n =16) treatment. The duration of
osteonecrosis was defined as the period of time the patients
had experienced pain before entering the study (4.7±3.5 vs.
4.1±2.3 months, p =0.91). The time between radiological
diagnosis (MRI) and study entry was 1.5±0.8 months for
patients randomized to ibandronate and 1.6±1.1 months for
patients randomized to placebo (p =0.85).
Of the 30 patients who underwent randomization, 10 par-
ticipants (five in each treatment group) terminated the study
prior as scheduled (Fig. 1). A secondary objective of the study
was the dropout rate after the first 12 weeks due to persistent
pain in affected knee. A total of seven patients (ibandronate,
n =2; placebo, n =5) terminated the study at week 12. De-
crease in pain score in these patients was significantly less
pronounced as compared to participants continuing the study
after 12 weeks (mean percent change in VAS, −12.8 vs.
−68.6 %, p <0.01). Randomization to either ibandronate or
placebo did not influence the dropout rate with similar pro-
portions of early study termination in both ibandronate- and
placebo-treated subjects (Fisher’s exact test, p =0.39). After
24 weeks, another three patients (all randomized to
ibandronate) dropped out in all cases due to persistent pain.
Patients were referred to orthopedic surgeons for total knee
replacement. Overall, a total number of 23 participants were
followed until week 12 (ibandronate, n =12; placebo, n =11),
whereas 20 patients completed the study per protocol
(ibandronate, n =9; placebo, n =11; Fig. 1).
Baseline characteristics
Characteristics of the study population at baseline are
displayed in Table 1. Except for older age in patients random-
ized to ibandronate treatment (p =0.01 vs. placebo), there were
no statistically significant differences between the two groups
in terms of demographic, clinical, and biochemical character-
istics. Specifically, pain score (VAS score) and physical func-
tion (assessed by WOMAC and IKDC questionnaires) were
similar at baseline. Both treatment groups were comparable in
the distribution of baseline severity of osteonecrosis in medial
or lateral femoral condyles. All patients had unilateral affection
(left knee, n =14, right knee, n =16) with osteonecrotic chang-
es either at the medial or lateral femoral condyles.
Clinical, functional, and biochemical outcome measures
After 12 weeks of treatment, significant decrease in pain score
(VAS) was observed in both ibandronate- and placebo-treated
patients. After adjustment for age, sex, and osteonecrosis type,
VAS score decreased by −2.98 (95 % CI, −4.34 to −1.62)
points in the ibandronate group and by −3.59 (95 % CI, −5.07
to −2.12) points in the placebo group (Table 2, Fig. 2). Treat-
ment effect was not different between the groups (p =0.54);
our results rejected the null hypothesis for the primary study
endpoint.
Whereas pain score did not change between weeks 12 and
48 in ibandronate-treated patients (p =0.37), placebo-treated
14 were assigned
to receive IV ibandronate
16 were assigned
to receive placebo
2 drop-outs at week 12 
due to persistent pain
for salvage therapy
(2° study endpoint)
9 terminated study
per protocol
11 terminated study
per protocol
3 drop-outs at week 24 
due to persistent pain
5 drop-outs at week 12 
due to persistent pain
for salvage therapy
(2° study endpoint)
30 patients underwent randomization
Fig. 1 Randomization and
follow-up
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Table 1 Baseline characteristics
of the study population by treat-
ment group
Data are given as mean±SD or n
(%)
WOMAC Western Ontario and
McMaster Universities osteoar-
thritis index, IKDC International
Knee Documentation Committee
aMannWhitneyU test or Fisher’s
exact test
Characteristics Ibandronate
(n =14)
Placebo
(n =16)
P valuea
Women 7 (50.0) 14 (87.5) 0.05
Age (years) 62.4±7.7 52.7±8.2 0.01
BMI (kg/m2) 27.7±3.7 31.1±6.2 0.10
Features of osteonecrosis
Cause
SONK 8 (57.1) 9 (56.2)
Minor trauma 4 (28.6) 5 (31.3) 0.99
Postarthroscopy 2 (14.3) 2 (12.5)
Side affected, left/right 9 / 5 5 / 11 0.07
Duration of osteonecrosis (mts) 4.7±3.5 4.1±2.3 0.91
Visual analog scale (pain score) 5.39±1.95 4.97±2.15 0.62
WOMAC global 3.65±2.56 3.21±1.83 0.61
WOMAC function 3.60±2.62 3.28±1.93 0.99
IKDC 35.36±17.55 41.14±10.45 0.41
MR imaging,
Grading bone marrow edema
4 2 (14.3) 0
3 6 (42.9) 8 (50.0) 0.49
2 5 (35.7) 5 (31.25)
1 1 (7.1) 3 (18.75)
MR imaging,
Grading osteonecrosis
4 0 0
3 4 (28.6) 1 (6.25) 0.14
2 9 (64.3) 10 (62.5)
1 1 (7.1) 5 (31.25)
Alkaline phosphatase (U/L) 63.14±18.31 72.94±20.19 0.19
PINP (μg/mL) 35.68±10.07 37.83±14.20 0.99
CTX (ng/mL) 0.335±0.112 0.264±0.151 0.10
25 (OH) vitamin D (ng/mL) 20.64±8.61 18.19±9.17 0.55
Table 2 Change in clinical and
biochemical measures during
treatment (adjusted outcome
change from baseline to week 12).
Adjustments were made for age,
sex, and type of osteonecrosis
WOMAC Western Ontario and
McMaster Universities osteoar-
thritis index, IKDC International
Knee Documentation Committee
a Dunnett-Hsu adjustment
Outcome Treatment Adjusted mean change 95 % CI p valuea
Δ VAS (pain score) Placebo −3.59 −5.07 to −2.12 0.54
Ibandronate −2.98 −4.34 to −1.62
ΔWOMAC function Placebo −2.64 −4.57 to −0.72 0.29
Ibandronate −1.31 −2.86 to 0.24
ΔWOMAC global Placebo −2.66 −4.50 to −0.84 0.24
Ibandronate −1.27 −2.74 to 0.19
Δ IKDC Placebo 28.58 13.78 to 43.38 0.13
Ibandronate 10.99 −4.04 to 26.03
Δ ALP (U/L) Placebo −7.97 −16.35 to 0.43 0.71
Ibandronate −10.10 −17.83 to −2.38
Δ PINP (μg/mL) Placebo −4.19 −11.53 to 3.14 0.06
Ibandronate −13.72 −20.62 to −6.81
Δ CTX (ng/mL) Placebo 0.042 −0.044 to 0.129 <0.01
Ibandronate −0.143 −0.223 to −0.064
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subjects showed significant further decrease in VAS score
between weeks 12 and 48 (p =0.01). At the end of the study
after 48 weeks, however, no significant between-group differ-
ence in pain score (VAS) was observed (Fig. 2).
Functional outcome as assessed by theWOMAC score and
the IKDC form improved after 12 weeks in the placebo group,
but not in ibandronate-treated patients (Table 2). The between-
group difference in all function scores was not significant
(WOMAC function, p =0.29; WOMAC global, p =0.24;
IKDC, p =0.13).
Changes in serum CTX, PINP, and alkaline phosphatase
after 12 weeks are shown on Table 2. Ibandronate treatment
resulted in significant decreases in serum levels of CTX (adjust-
ed mean change, −0.143 ng/mL; 95 % CI, −0.223 to −0.064),
PINP (adjusted mean change, −13.72 μg/mL; 95 % CI, −20.62
to −6.81) and ALP (adjusted mean change, −10.10 U/L; 95 %
CI, −17.83 to −2.38), whereas biochemical markers of bone
turnover were not significantly altered in placebo-treated sub-
jects. The between-group difference was significant for CTX (p
<0.01), but not for PINP (p =0.06) and ALP (p=0.71).
Radiological outcome measures
MRI evaluation revealed significant changes in the degree of
bone marrow edema and degree of osteonecrosis in both
ibandronate- and placebo-treated patients. Specifically, after
48 weeks, adjusted mean change in degree of bone marrow
edema was −2.05 (95 % CI, −3.17to −0.95) after ibandronate
treatment and −1.52 (95 % CI, −2.73 to −0.31) after placebo
treatment. Similarly, adjusted mean change in degree of
osteonecrosis was −0.83 (95 % CI, −1.33 to −0.34) after
ibandronate treatment and −0.92 (95 % CI, −1.45 to −0.39)
after placebo treatment. Treatment effects were not different
between the groups after 12 and 48 weeks for both degree in
bone marrow edema (p =0.97 and p =0.48, respectively) and
degree of osteonecrosis (p =0.20 and p =0.79, respectively).
Discussion
Our results do not support the hypothesized superiority of
bisphosphonate treatment in patients with spontaneous or
postarthroscopic osteonecrosis of the knee. Specifically, intra-
venous ibandronate had no beneficial effect on clinical, func-
tional, and radiological outcomes of osteonecrosis in the fem-
oral condyles over and above anti-inflammatory medication.
The results of this randomized, double-blind, and placebo-
controlled study are in contrast to previous observational stud-
ies [19–21] and case reports [18] suggesting a favorable effect
of bisphosphonate treatment. In a consecutive case series of
five patients suffering from spontaneous osteonecrosis of the
knee, intravenous application of ibandronate resulted in early
clinical improvement and remission of bone marrow edema in
all patients [20]. A larger case series including 17 patients with
osteonecrosis of the knee found that alendronate treatment over
6 months resulted in complete radiographic (MRI) recovery in
59 % of patients as compared to a historical untreated control
group in which only 12 % of patients showed radiological
improvement [21]. Importantly, all these studies and case series
are limited by small sample size, short duration, and the lack of
a control group which does not allow comparing definitively
beneficial effects of bisphosphonates against the natural course
of disease.
Our study is the first randomized, placebo-controlled trial to
assess the effect of bisphosphonates in patients with
osteonecrosis of the knee. After 12 weeks of treatment, signif-
icant decrease in VAS was observed in both ibandronate- and
placebo-treated patients. After adjustment for age, sex, and
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osteonecrosis type, VAS score decreased by −2.98 (95 % CI,
−4.34 to −1.62) points in the ibandronate group and by −3.59
(95 % CI, −5.07 to −2.12) points in the placebo group. Impor-
tantly, treatment effect was not different between the groups
rejecting the null hypothesis for the primary study endpoint.
After 6 months, VAS score decreased by 67 % in ibandronate-
treated patients and by 75 % in placebo-treated subjects. Inter-
estingly, the decrease of pain score after 6 months was to a
similar extent as what we have observed in the aforementioned
uncontrolled study using pamidronate and alendronate (decrease
by 80 %) [19].
Changes of questionnaires assessing functionality were
comparable in both treatment groups without superiority of
ibandronate treatment. Similarly, treatment effects in radiolog-
ical outcome were not different between the groups. MRI
evaluation revealed significant changes in the degree of bone
marrow edema and degree of osteonecrosis in both
ibandronate- and placebo-treated patients. Finally, randomiza-
tion to either ibandronate or placebo did not influence the
dropout rate with similar proportions of early study termina-
tion in both treatment groups.
Overall, our results indicate that bisphosphonates have no
major influence on clinical outcome in the course of disease.
Changes observed for primary and secondary endpoints in
both ibandronate- and placebo-treated patients were mostly
within the magnitude which would be considered clinically
significant; hence, in most patients, osteonecrosis of the knee
may be self-limited. This is strengthened by the fact that as a
result of antiresorptive treatment with ibandronate bone turn-
over markers (i.e., serum CTX) was significantly suppressed
whereas biochemical markers of bone turnover were not al-
tered in placebo-treated subjects. As bisphosphonates prefer-
entially concentrate at skeletal sites with active remodeling
[33], ibandronate treatment must have ensued significant con-
centrations in affected femoral condyles to provoke beneficial
clinical effects during healing process. However, the degree of
suppression of bone turnover with the treatment regimen was
modest; hence, whether other antiresorptive agents with more
potent suppression of bone remodeling (i.e., zoledronic acid or
denosumab) may have exerted a stronger effect on outcome
measures remains unclear.
In experimental animal studies, it has been shown that
alendronate and more recently zoledronate treatment prevents
resorption of necrotic bone during revascularization [9, 34].
There are several reports of successful bisphosphonate treat-
ment of the transient osteoporosis of the hip or osteonecrosis
of the femoral head [14, 17, 35–37]. In one of the few
randomized-controlled trial with alendronate treatment in 40
patients with atraumatic osteonecrosis of the femoral head
with an involvement of at least 30 % of the head, only one
patient in the alendronate group needed a total hip arthroplasty
whereas 16 subjects in the control group underwent total hip
arthroplasty over an observation period of 28 months [14].
Recently, data from a randomized, double-blind, placebo-
controlled study investigating the effect of alendronate in the
prevention of collapse of the femoral head in 52 patients with
nontraumatic osteonecrosis have been published [38]. In con-
trast to all non-placebo-controlled studies, Chen et al. ob-
served no significant difference in clinical and radiographic
outcomes and disease progression between alendronate- and
placebo-treated subjects. Hence, based on randomized,
placebo-controlled trials, clinical significant effects of
bisphosphonates in osteonecrosis of the femoral head as well
as the knee have to be questioned.
This present study’s findings should be interpreted within
the context of its strengths and limitations. Our study using a
randomized, placebo-controlled study design suggests for the
first time that bisphosphonates, i.e., intravenous ibandronate
have no beneficial effect on this disease outcome. The study is
limited by short follow-up. Longer follow-up time, however,
is unlikely to have modulated our findings as nearly all pa-
tients presented with major reduction in pain score after
48 weeks (VAS score 0–2). Secondly, the sample size was
small, although the number of enrolled subjects reached the
target based on the power estimate. We adjusted for imbal-
ances in baseline characteristics (age, sex distribution, and
type of osteonecrosis); nevertheless, due to small sample size,
residual confounding due to differences in these variables
cannot be completely ruled out. Thirdly, treatment was initi-
ated with some delay after osteonecrosis was diagnosed and
patients were not randomized for the size of their lesions.
Clearly, our findings are not generalizable to secondary forms
of osteonecrosis of the knee or to osteonecrosis of other
localizations. Further randomized studies are needed to con-
firm our findings and explore alternative bisphosphonates
with selective higher affinity to bone surfaces to crystallize
optimal nonsurgical management and surgical indications for
spontaneous or postarthroscopic osteonecrosis of the knee.
We conclude that in patients with spontaneous osteonecrosis
of the knee, intravenous ibandronate has no beneficial effect
over and above anti-inflammatory medication. Hence, bisphos-
phonate therapy for the use of osteonecrosis of the knee should
be used with caution.
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